Tenaya Therapeutics recebe notificação da Nasdaq sobre preço mínimo de oferta e altera plano de ações
H.C. Wainwright reduz preço-alvo das ações da Tenaya Therapeutics para US$ 3 após dados de ensaio ARVC
S&P 500 Down 1%; Broadcom Earnings Top Views - Applied Therapeutics (NASDAQ:APLT), Broadcom (NASDAQ:AVGO)
Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings - Akanda (NASDAQ:AKAN), Applied Therapeutics (NASDAQ:APLT)
Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC - Slideshow (NASDAQ:TNYA) 2025-12-11